ABSTRACT: Chagas disease is a neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi. Here we report crystal structures of the galactofuranose biosynthetic enzyme UDP-galactopyranose mutase (UGM) from T. cruzi, which are the first structures of this enzyme from a protozoan parasite. UGM is an attractive target for drug design because galactofuranose is absent in humans but is an essential component of key glycoproteins and glycolipids in trypanosomatids. Analysis of the enzyme−UDP noncovalent interactions and sequence alignments suggests that substrate recognition is exquisitely conserved among eukaryotic UGMs and distinct from that of bacterial UGMs. This observation has implications for inhibitor design. Activation of the enzyme via reduction of the FAD induces profound conformational changes, including a 2.3 Å movement of the histidine loop (Gly60-Gly61-His62), rotation and protonation of the imidazole of His62, and cooperative movement of residues located on the si face of the FAD. Interestingly, these changes are substantially different from those described for Aspergillus f umigatus UGM, which is 45% identical to T. cruzi UGM. The importance of Gly61 and His62 for enzymatic activity was studied with the site-directed mutant enzymes G61A, G61P, and H62A. These mutations lower the catalytic efficiency by factors of 10−50, primarily by decreasing k cat . Considered together, the structural, kinetic, and sequence data suggest that the middle Gly of the histidine loop imparts flexibility that is essential for activation of eukaryotic UGMs. Our results provide new information about UGM biochemistry and suggest a unified strategy for designing inhibitors of UGMs from the eukaryotic pathogens.
C hagas disease (aka American trypanosomiasis) is a major global health concern. 1 The disease is caused by the protozoan parasite Trypanosoma cruzi and spread by triatomine insects, which carry the parasite in their gut. Chagas disease is one of several neglected tropical diseases, i.e., chronic infectious diseases that are prevalent in poor countries and underemphasized by society relative to the number of people affected. The disease is endemic in Latin America, and at least 10 million people worldwide are estimated to be infected with T. cruzi. 1 Infection mainly occurs through contact with the feces of triatomine bugs, but transmission also occurs via blood transfusions, organ transplants, ingestion of contaminated food, and mother-to-child. 1 It is estimated that 30% of Chagas patients will develop heart damage in the late chronic stage of the disease, leading to death caused by arrhythmia in early adulthood. 1 More than 10 000 deaths occur annually from Chagas disease, and the burden of disease is the highest for any parasitic disease in the Western hemisphere. 1, 2 Chagas is unusual among neglected diseases in that it is spreading to nonendemic areas, including the United States, Canada, and Europe. 2, 3 The two drugs used for treatment, benznidazole and nifurtimox, have significant side effects and uncertain efficacy, 4−6 and there is no vaccine available. The prevalence of the disease, the spread to new regions of the globe, and the lack of adequate medications emphasize the need for new drugs to treat Chagas disease.
The flavoenzyme UDP-galactopyranose mutase (UGM) has received attention recently as a drug design target for neglected tropical diseases. 7−9 UGM plays a central role in the biosynthesis of galactofuranose (Galf) by catalyzing the conversion of UDP-galactopyranose (UDP-Galp) to UDPgalactofuranose (UDP-Galf) ( Figure 1 ). Galf has never been found in humans but is an essential component of the cell wall and extracellular matrix of many pathogenic bacteria, fungi, and protozoa. 8, 9 UGM and Galf are widely distributed in pathogenic protozoa. 7, 8 In particular, Galf is present in glycoinositolphospholipids and glycosylphosphatidylinositol anchor proteins of T. cruzi. 10, 11 In the related parasite, Leishmania major, which causes leishmaniasis, Galf is present in the membrane anchor of the lipophosphoglycan and in glycoinositolphospholipids. 12 These glycoconjugates are highly expressed throughout the life cycle of these parasites and are important for their survival and proliferation. 12−14 Galf-containing glycoconjugates are thought to be involved in the mechanism of myocardiac invasion by T. cruzi. 15 In Leishmania, lipophosphoglycans are essential for the binding and detachment of the parasite to the midgut of the vector insect and thus for transmission of the parasite to the human host. 16, 17 Furthermore, studies with lipophosphoglycan deletion mutants in L. major demonstrated that these glycosylated structures are involved in resistance to oxidative stress and evasion of the human immune system. 16, 17 Moreover, a UGM deletion mutant of L. major exhibits attenuated virulence. 7 In summary, Galf-containing molecules of protozoan parasites function in host-specific cell recognition, growth, and pathogenesis. Since UGM is essential for the biosynthesis of Galf, inhibition of the enzyme is an attractive approach for finding new drugs for Chagas disease and leishmaniasis.
The potential for inhibitor design and the uniqueness of the chemical mechanism of UGM have motivated structural studies of the enzyme. Several crystal structures of bacterial UGMs have been determined. 18−23 These structures revealed the essential UGM fold and provided insight into several aspects of UGM biochemistry, including the structural basis of substrate recognition and the catalytic mechanism. Eukaryotic UGMs have received less attention. We recently reported crystal structures and small-angle X-ray scattering analysis of UGM from the pathogenic fungus Aspergillus f umigatus (AfUGM), which was the first structural data for any eukaryotic UGM. 24 Shortly thereafter, Sanders' group published structures of AfUGM based on a different (space group P1) crystal form. 25 Our analysis of the data showed that AfUGM has several extra secondary and tertiary structural elements that are not found in bacterial UGMs yet are important for substrate recognition and tetramerization. 24 The AfUGM structures also revealed large conformational changes that accompany substrate binding, which is highly relevant for inhibitor design. As part of our ongoing studies of UGM from eukaryotic pathogens, we report crystal structures of oxidized and reduced T. cruzi UGM (TcUGM) complexed with the inhibitor UDP. Analysis of the UDP binding site suggests a common strategy for designing inhibitors of UGMs from eukaryotic pathogens, including T. cruzi, L. major, and A. f umigatus. Comparison of the structures of oxidized and reduced TcUGM reveals profound conformational changes induced by reduction of the FAD cofactor, which provides new information about the molecular mechanism of enzyme activation by reducing agents. These results provide a foundation for inhibitor design and insight into UGM biochemistry.
■ EXPERIMENTAL PROCEDURES
Crystallization. TcUGM was expressed and purified as described previously. 26 Crystallization studies used TcUGM at 7−8 mg/mL in 150 mM NaCl buffered at pH 7.5 with either 50 mM phosphate or 50 mM HEPES. Prior to crystallization, the enzyme was incubated with 10 mM UDP for 30 min. Crystallization experiments were performed at 20°C using sitting drop vapor diffusion with the drops formed by mixing 1.5 μL each of the protein and reservoir solutions. Several commercially available crystallization screens were used to identify initial crystallization conditions. Promising conditions were obtained with reservoirs containing ammonium sulfate and HEPES buffer. Small yellow crystals appeared after 2 weeks. Larger crystals were obtained within a week via microseeding. The optimized crystallization reservoir contains 1.0 M ammonium sulfate, 0.5% poly(ethylene glycol) 8000, and 0.1 M HEPES at pH 7.5. The crystals were cryoprotected in 1.2 M ammonium sulfate, 0.1 M HEPES pH 7.5, and 25% glycerol before plunging into liquid N 2 .
The space group is P6 5 22 with unit cell dimensions of a = 143 Å and c = 354 Å. Based on the method of Matthews 27 and assuming ∼50% solvent content, the asymmetric unit is predicted to contain four protein molecules, which implies V M of 2.4 Å 3 /Da (48% solvent). However, molecular replacement calculations show that the asymmetric unit contains just two protein molecules (vide inf ra), which corresponds to 74% solvent and V M of 4.8 Å 3 /Da. Crystals of the TcUGM−UDP complex with the FAD in the reduced state were prepared by soaking the aforementioned crystals in 1.2 M ammonium sulfate, 0.1 M HEPES pH 7.5, 60 mM sodium dithionite, and 25% ethylene glycol. Once the crystals turned from yellow to colorless, they were flash-cooled by plunging into liquid N 2 .
X-ray Diffraction Data Collection, Phasing, and Refinement. Diffraction data were collected at the Advanced Photon Source. The data set for oxidized TcUGM−UDP was collected at beamline 19-ID and processed using HKL3000. 28 The data set for reduced TcUGM−UDP was collected at beamline 24-ID-C, and the data were integrated using XDS 29 and scaled with SCALA 30 via CCP4i. 31 Data processing statistics are listed in Table 1 .
The phase problem for oxidized TcUGM−UDP was solved using molecular replacement as implemented in MOLREP. 32 The search model was derived from the structure of AfUGM (PDB code 3UTE 24 ). Chainsaw was used to create a model in which all the side chains were pruned to the β-carbon atom. The calculations produced a solution having two molecules in the asymmetric unit with R-factor of 0.6 and score of 0.3. The model was manually edited and built using COOT 33 and refined using PHENIX. 34 An advanced model of oxidized TcUGM-UDP was used as the starting point for refinement of reduced TcUGM−UDP. Refinement statistics are listed in Table 1 . We note that, for both the oxidized and reduced TcUGM−UDP structures, the two molecules in the crystallographic asymmetric unit are identical within experimental error. Mutagenesis and Kinetics. The site directed mutant enzymes G61A, G61P, and H62A were created using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) following the protocol supplied by the manufacturer. All the mutants were expressed and purified following the procedures previously described for the wild-type enzyme. 26 The activities of the TcUGM mutant enzymes G61A, G61P, and H62A were determined using steady-state kinetics analysis as described previously. 26, 35 In these experiments, the rate of conversion of UDP-Galf to UDP-Galp was measured at 37°C and pH 7.5 in the presence of 20 mM dithionite. The reverse reaction was studied because the equilibrium between UDPGalp and UDP-Galf favors the former by the ratio of 13:1. Synthesis of UDP-Galf was performed as described previously. 26, 36 ■ RESULTS Overall Fold and Oligomeric State. The structures of oxidized and reduced TcUGM complexed with the inhibitor UDP were determined at 2.25 Å resolution (Table 1) . These are the first structures of UGM from a parasitic pathogen and the second structure of a eukaryotic UGM.
TcUGM has a mixed α/β-fold that comprises three domains ( Figure 2A ). Domain 1 is the largest and consists of three sections of the polypeptide chain (residues 4−86, 199−291, and 397−475). This domain functions primarily in binding FAD and has a Rossmann fold as its core. Domain 2 is a bundle of α-helices and participates in substrate binding (residues 101−198). Domain 3 features a twisted, 7-stranded β-sheet that sits atop a 15-residue α-helix (residues 87−100, 292−396). This domain also contributes to substrate binding.
AfUGM is the closest structural neighbor of TcUGM in the Protein Data Bank (PDB). The two enzymes are 45% identical in sequence, and the two structures superimpose with a rootmean-square deviation of 1.1 Å ( Figure 2B ). Although they share a common overall fold, several local variations between the two structures are evident ( Figure 2B ). For example, a loop of domain 1 is longer in TcUGM, whereas a loop in domain 3 is longer in AfUGM. The significance of these differences is not obvious. In contrast, other differences are substantive in that they appear to dictate the oligomeric state formed in solution (see Discussion). These include the longer α-helix in domain 2 of AfUGM and the additional α-helix at the C-terminus of AfUGM ( Figure 2B ).
The crystal structure is consistent with TcUGM being monomeric in solution. Analysis of protein−protein interfaces in the crystal lattice using the PDBePISA 37 revealed no oligomers predicted to be stable in solution. Furthermore, neither the AfUGM tetramer nor its constituent dimers are present in the TcUGM crystal lattice. Moreover, none of the dimeric assemblies of bacterial UGMs are observed in the lattice. It is concluded that TcUGM forms a monomer in solution, which is consistent with recent size exclusion chromatography data. 26 Binding of UDP. The structures of TcUGM complexed with UDP were determined from crystals that had been grown in the presence of the inhibitor. Electron density maps clearly indicated that UDP is bound in the active site with full UDP forms several interactions with TcUGM ( Figure 3 ). The uracil ring is wedged between the aromatic rings of Tyr100 and Phe152, which positions the base to form three hydrogen bonds with the side chain of Gln103 and backbone of Phe102. Thus, the hydrogen-bonding potential of uracil is fully satisfied. The ribose hydroxyl groups of UDP interact with Asn157 and Trp161. The pyrophosphate directly interacts with Arg327 and three tyrosine residues (317, 395, and 429). Several watermediated hydrogen bonds are also observed. In summary, all three chemical groups of UDPbase, ribose, and pyrophosphateare in direct electrostatic contact with the enzyme, which results in a plethora of stabilizing interactions.
Conformational Changes Induced by FAD Reduction. The FAD of UGM functions as a nucleophile that attacks the anomeric carbon atom of the galactose moiety (C1 in Figure 1 ) in an S N 2-like reaction; thus, enzymatic activity requires that the FAD be in the reduced state (FADH − ). 26, 38, 39 Structures of oxidized and reduced TcUGM were determined to understand the mechanism by which the enzyme is activated by FAD reduction.
The structure of the oxidized enzyme was determined from crystals that were grown and cryoprotected without reducing agent. These crystals were yellow, which is characteristic of the oxidized state of FAD. The structure of the reduced enzyme was determined from crystals of the oxidized enzyme that were soaked in reducing agent (dithionite) prior to flash-cooling in liquid nitrogen. The crystals turned colorless during soaking, which indicated that the FAD was reduced.
Reduction of the FAD causes substantial conformational changes in the active site (Figure 4 ). In the oxidized enzyme, the conserved histidine loop (Gly60-Gly61-His62) adopts an unprecedented conformation for UGMs in which it is retracted from the FAD isoalloxazine ( Figure 4A ). This conformation is stabilized by hydrogen bonds between Asp58 and the backbone of Gly61 and His62. Upon reduction, the histidine loop shifts 2.3 Å toward the isoalloxazine ( Figure 4B ). In this conformation, the carbonyl of Gly61 accepts a hydrogen bond from the flavin N5, which is a hydrogen bond donor in the reduced state. This hydrogen bond is observed in all reduced UGM structures and is thus thought to be essential for stabilizing the reduced flavin. Movement of the histidine loop toward the reduced flavin triggers other conformational changes ( Figure 4C ). Asp58 and Thr212 rotate to engage each other in a hydrogen bond. Note that the rotation of Asp58 also allows a hydrogen bond with Ser 48. Finally, Met347 moves into the space vacated by Gly61 and Asp58, while Gln434 rotates away from His62.
The imidazole ring of His62 becomes protonated and flips by 180°upon flavin reduction. Although the protonation state and value of χ2 of histidine cannot be determined solely from electron density at 2.25 Å resolution, these attributes can be inferred from hydrogen-bonding considerations and knowledge of the preferred tautomer of neutral histidine. Analysis of hydrogen bonding with MolProbity 40 suggests that in the oxidized enzyme, His62 adopts the neutral τ tautomer with the imidazole accepting a hydrogen bond from Gln434 and donating a hydrogen bond to the carbonyl of Leu59 ( Figure  4A ). We note that τ is the preferred tautomer of neutral His. In the reduced enzyme, on the other hand, hydrogen bonding is maximized with the imidazole protonated and flipped by 180°t o allow hydrogen bonds with the carbonyl of Gly60 and the FAD 2′-hydroxyl ( Figure 4B ). Note that the assigned protonation states of His62 are consistent with the fact that the oxidized FAD is uncharged and the reduced FAD is anionic (FADH − ). Reduction also affects the conformation of the isoalloxazine ( Figure 5 ). In the oxidized state, the electron density maps are consistent with a planar isoalloxazine ( Figure 5A ). In the reduced enzyme, the FAD exhibits a butterfly like conformation in which the pyrimidine ring bends 7°out of the plane such that the si face is concave ( Figure 5B ). This conformation is identical to that of reduced AfUGM.
Site-Directed Mutagenesis of the Histidine Loop. The importance of the histidine loop for catalytic activity was investigated using site-directed mutagenesis. Gly61 and His62 were targeted for mutagenesis because they form hydrogen bonds to FADH − and exhibit large conformational changes upon flavin reduction. Gly61 is conserved among eukaryotic UGMs but appears as Ala or Pro in bacterial UGMs. Therefore, the mutant enzymes G61A and G61P were created. His62 is universally conserved among UGMs, and the H62A mutant enzyme was created. (For reference, Gly60 is also conserved in all UGMs.) Mutation of the histidine loop of TcUGM is highly detrimental to activity ( Figure S1 of Supporting Information and Table 2 ). Mutation of Gly61 to Ala reduces k cat by a factor of 70 but reduces K m by only a factor of 3. As a result, the catalytic efficiency of G61A is only 4% of that of TcUGM. Similarly, mutation of Gly61 to Pro substantially decreases k cat (factor of 16) but has less effect on K m . The catalytic efficiency of this mutant enzyme is 10% of that of TcUGM. Mutation of His62 to Ala has a profound effect on k cat ; this mutation decreases k cat by over 300. The catalytic efficiency of H62A is just 2% compared to that of TcUGM. These results suggest that Gly and His at positions 61 and 62 are important for efficient catalysis by TcUGM. Furthermore, the histidine loop sequences found in bacterial UGMs (GAH, GPH) are poorly tolerated by TcUGM.
■ DISCUSSION
Inhibitor design is aided by knowledge of substrate recognition, and substrate recognition appears to be exquisitely conserved among eukaryotic UGMs. Comparison of the structures of TcUGM and AfUGM complexed with UDP show that the UDP binding sites are identical ( Figure 6 ). All residues that contact UDP, either directly or via water molecules, are present in both enzymes. Furthermore, the conformations of these residues, as well as their interactions with UDP, are identical in the two structures. The structural similarity extends even to the water molecules that mediate protein−inhibitor interactions ( Figure 6 ). Moreover, all residues that contact UDP or UDPGalp in the TcUGM and AfUGM crystal structures are also present in many other eukaryotic UGMs, including L. major UGM (Figure 7, triangles) . Thus, it is likely that the AfUGM and TcUGM structures are representative of eukaryotic UGMs with regard to substrate binding.
This analysis suggests a unified strategy for designing inhibitors of UGMs from T. cruzi, L. major, and A. f umigatus, which are three important eukaryotic pathogens. For example, a compound that binds in the active site of any of these enzymes is predicted to also inhibit the other ones. Therefore, screening efforts could be focused on one enzyme. Our results also suggest that testing known inhibitors of bacterial UGMs may not be an optimal strategy for identifying inhibitors of eukaryotic UGMs. We previously showed that the substrate site of eukaryotic UGMs differs substantially from that of bacterial UGMs, particularly in the region around the UMP moiety (see Figure S2 of Dhatwalia et al. 24 ). Thus, compounds that target the UMP site of bacterial UGMs will not likely have high affinity for eukaryotic UGMs. In summary, the very high structural similarity of the substrate binding sites of TcUGM and AfUGM raises the possibility of finding a single compound that inhibits multiple eukaryotic UGMs. This observation simplifies inhibitor discovery.
The structures also provide insight into the surprising lack of conservation of the oligomeric state by eukaryotic UGMs. TcUGM is the first example of a monomeric UGM. As we reported previously, 24 AfUGM forms a dimer-of-dimers tetramer having 222 point group symmetry ( Figure S2 ). Three conformational differences between the two enzymes account for the difference in oligomeric state. First, AfUGM has an additional 7-residue α-helix at the C-terminus ( Figure 2B ), and this helix packs against domain 1 of another protomer in the tetramer ( Figure S2 ). The absence of this helix in TcUGM obviously precludes formation of this critical interface. The second point of departure occurs in the two parallel helices of domain 2 ( Figure 2C ). These helices form an intersubunit 4-helix bundle across one of the 2-fold axes in the AfUGM tetramer ( Figure S2B ). The 4-helix bundle in AfUGM has a tightly packed hydrophobic interior. In contrast, TcUGM has long charged and polar side chains on these helices, which would inhibit formation of the hydrophobic bundle ( Figure  2C ). In particular, if a theoretical tetramer is built from TcUGM monomers, Arg186, Arg114, and Gln190 form steric clashes with the symmetry related helices. The potential for these clashes presumably prevents TcUGM from forming this interface. Finally, TcUGM is unable to form the four intersubunit hydrogen bonds that are present in the centroid of the AfUGM tetramer ( Figure S2A, inset) . These hydrogen bonds involve Arg133, which is located at the C-terminus of one of the helices of the 4-helix bundle ( Figure 2C ). Because the helix is a full turn shorter in TcUGM, these intersubunit interactions cannot be formed. These conformational differences account for the difference in the oligomeric states of TcUGM and AfUGM.
The TcUGM structures provide new information about conformational changes associated with activation of the enzyme via reduction of the FAD (Figures 4 and 5) . Reduction of the FAD causes several concerted changes in the protein. The histidine loop moves by 2.3 Å ( Figure 4C ). His62, a universally conserved residue in UGMs, flips by 180°and becomes protonated. The protonation of His62 may help stabilize the negative charge of the reduced FAD. The side chains of Asp58 and Thr212 rotate by 180°. Met 347 and Gln434 move by 1.6 Å. It is notable that all of these residues are located on the side of the FAD that is opposite to the substratebinding site. Thus, two critical aspects of function are delegated to distinct regions of the protein: maintaining the redox state is the responsibility of residues on the si face FAD, while substrate binding is performed by residues on the re side. These conformational changes are consistent with the generally accepted chemical mechanism of UGM. The prevailing mechanism is an S N 2-type displacement in which the N5 atom of the reduced FAD functions as the nucleophile Figure 7 . Amino acid sequence alignment of UGMs from T. cruzi, L. major, and A. f umigatus. The secondary structure elements above and below the alignment are from the TcUGM and AfUGM structures, respectively. The yellow box denotes the histidine loop, which moves in response to changes in the FAD redox state. The green triangles denote residues that contact UDP-Galp; note that they are 100% identical in the three enzymes.
that attacks the anomeric carbon of galactose to form a covalent intermediate and displace UDP. 38, 39 This mechanism was recently validated for TcUGM. 26 Activity thus requires that the FAD be reduced. The coordinated movements of the histidine loop, Asp58, Thr212, and the FAD isoalloxazine in TcUGM have two salient effects. First, a hydrogen bond is created between the N5 atom of the reduced flavin and the carbonyl oxygen atom of the residue preceding the conserved histidine (Gly61). This interaction is seen in all reduced UGMs and is therefore thought to be essential for stabilizing the reduced flavin. Second, curvature is induced in the flavin isoalloxazine such that the si face is concave. Bending of the isoalloxazine in this direction is consistent with the FAD functioning as a nucleophile. 19 Curiously, the conformational changes observed for TcUGM are different from those described for the close homologue AfUGM ( Figure 8 ). We previously reported structures of oxidized and reduced AfUGM based on a P6 5 22 crystal form. 24 Sanders' group subsequently reported P1 structures of AfUGM. 25 The structures of the reduced active sites are nearly identical in TcUGM and AfUGM ( Figure 8C ). However, in oxidized AfUGM, the His residue of the histidine loop is substantially displaced toward the pyrimidine portion of the isoalloxazine ( Figure 8B ), whereas in oxidized TcUGM the His residue is near the middle ring of the isoalloxazine ( Figure 8A ). Furthermore, in oxidized AfUGM, the carbonyl bond vector of the middle Gly residue is directed away from the isoalloxazine ( Figure 8B, Gly62) , whereas the corresponding carbonyl of oxidized TcUGM points toward the isoalloxazine (Figure 8A,  Gly61) . Reduction of the FAD in AfUGM causes a 6−8 Å movement of the imidazole ring of the conserved histidine ( Figure 8 ). As described above, the movement of the histidine loop in TcUGM is more subtle. It should be noted that elucidation of redox-linked conformational changes for AfUGM is complicated by the adventitious binding of sulfate ions to the oxidized active site of the P6 5 22 crystal form (PDB code 3UTE) and weak electron density for the histidine loop and bound UDP in the oxidized P1 form (3UKH). Nevertheless, taken together, the AfUGM and TcUGM structures implicate flexibility of the histidine loop in the mechanism of enzyme activation.
The large conformational changes in the histidine loop observed in TcUGM and AfUGM appear to be unique to eukaryotic UGMs. Comparison of oxidized and reduced bacterial UGM structures shows that flavin reduction induces bending of the isoalloxazine but no substantial changes in the protein conformation. 19, 21, 22 Analysis of amino acid sequence conservation provides a rationale for why the histidine loop is static in bacterial UGMs and dynamic in eukaryotic UGMs. The histidine loop sequence of GGH is conserved among eukaryotic UGMs (Figure 7 ). In contrast, bacterial UGMs have either Ala or Pro in place of the second Gly. The extra Gly in the histidine loop most likely accounts for the increased flexibility of the loop in AfUGM and TcUGM.
This additional flexibility of the histidine loop appears to be important for function in TcUGM. Our mutagenesis data show that transplanting the bacterial sequences of GAH and GPH into TcUGM substantially decreases catalytic efficiency (Table  2 ). It is possible that the additional flexibility afforded by the extra Gly residue in TcUGM is needed to establish optimal hydrogen bonding between the histidine loop and FADH − . Although structures of the TcUGM histidine loop mutant enzymes are not available, it is possible that the loop-flavin hydrogen bonding is suboptimal in these impaired enzymes, which likely decreases the nucleophilic character of the reduced flavin. This idea is consistent with the markedly decreased k cat values of the histidine loop mutants.
Why eukaryotic UGMs undergo such large conformational changes upon activation is an open question. One possibility is that these conformational changes control the access of O 2 and reductant to the flavin. In the reduced enzyme, positioning the histidine loop close to the isoalloxazine N5−C4a edge helps protect the C4a atom of the reduced FAD from attack by O 2 ( Figure 4B) . Retraction of the loop upon oxidation perhaps allows open space for reducing agents to gain access to the oxidized flavin ( Figure 4A ). Regulation of function is another possibility. Conformational changes that are linked to the flavin redox state often serve a regulatory purpose. 42 Whether eukaryotic UGMs are subject to some sort of redox-linked regulation remains to be determined. 
